Neogenomics Inc (NEO) Stock AnalysisNEONeogenomics Inc

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others. It operates in the Healthcare sector (SERVICES-TESTING LABORATORIES industry).

While Neogenomics Inc shows potential for long-term growth, the current price of $16.35 is close to the lower end of analyst price targets, which range from $16 to $28. The stock has a low RSI of 33.107, indicating it may be oversold, but the forward P/E ratio is very high at 222.22, suggesting that the stock is expensive relative to its expected earnings. Additionally, the recent 5-day change of -11.48% raises concerns about short-term volatility. Therefore, it may be prudent to hold off on buying until there are clearer signs of recovery or a more favorable entry point.

9 analysts cover NEO: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 14.00.